



## Clene to Provide CNM-Au8® ALS Program Update

December 2, 2025

### Webcast set for 8:30 a.m. ET on December 3rd

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an investor call and webcast at 8:30 am ET on Wednesday, December 3, 2025. The webcast is accessible via the link below or the Investors section of the Company's website located [here](#).

#### Webcast Information:

**Title:** CNM-Au8 ALS Program Update

**Presenters:** Rob Etherington, CEO and President, Dr. Ben Greenberg, Head of Medical, Michael Hotchkin, Chief Development Officer and a KOL

**Date:** December 3, 2025

**Start Time:** 8:30 a.m. ET

**Webcast link:** [https://viaavid.webcasts.com/starthere.jsp?ei=1744985&tp\\_key=9fb9583d33](https://viaavid.webcasts.com/starthere.jsp?ei=1744985&tp_key=9fb9583d33)

**Dial number:** 1-877-407-0779 (US) or 1-201-389-0914 (international), Conference ID#13757380

The archived webcast will be available on the Company's website beginning approximately two hours after the event.

#### About Clene

Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. CNM-Au8<sup>®</sup> is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8<sup>®</sup> is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit [www.clene.com](http://www.clene.com) or follow us on [X](#) (formerly [Twitter](#)) and [LinkedIn](#).

#### About CNM-Au8<sup>®</sup>

CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8<sup>®</sup> is a federally registered trademark of Clene Nanomedicine, Inc.

#### Investor Contact

Kevin Gardner

LifeSci Advisors

[kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)

617-283-2856